Table 3.
Baseline characteristics and outcomes in patients with or without antecedent hypertension.
| Non-hypertension (N = 401) | Hypertension (N = 71) | p-value | |
|---|---|---|---|
| Ages, years (IQR) | 41 (31–50) | 59 (49–68) | <.001 |
| Male, n (%) | 216 (53.9) | 34 (47.9) | .352 |
| Diabetes mellitus, n (%) | 24 (6.0) | 13 (18.3) | <.001 |
| Coronary artery disease, n (%) | 4 (1.0) | 8 (11.3) | <.001 |
| COPD, n (%) | 4 (1.0) | 2 (2.8) | .207 |
| Cerebrovascular disease, n (%) | 3 (0.8) | 6 (8.5) | <.001 |
| Heart rate, bpm (IQR) | 88 (80–97) | 90 (78–99) | .435 |
| Systolic blood pressure, mmHg (IQR) | 125(115–136) | 133 (121–147) | .002 |
| Diastolic blood pressure, mmHg (IQR) | 80 (72–87) | 80 (74–89) | .413 |
| Oxygen saturation, % (IQR) | 97 (96–98) | 97 (95–98) | .809 |
| Oxygenation index on admission, mmHg (IQR) | 400.7 (337.6–472.2) | 343.5 (233.8–417.9) | .004 |
| Neutrophil, 109/L (IQR) | 3.4 (2.5–4.9) | 3.6 (3.0–5.1) | .069 |
| Lymphocyte, 109/L (IQR) | 1.2 (0.8–1.6) | 1.1 (0.6–1.5) | .041 |
| Haemoglobin, g/L (IQR) | 140.0 (127.0–153.5) | 134.0 (123.0–150.0) | .031 |
| Albumin, g/L (IQR) | 43.20 (40.00–46.10) | 40.45 (36.00–44.15) | <.001 |
| AST, U/L (IQR) | 25.0 (20.0–34.0) | 31.8 (24.5–40.5) | <.001 |
| UA, umol/L (IQR) | 268.0 (204.0–342.0) | 292.0 (216.3–408.0) | .055 |
| Total triglyceride, mmol/L (IQR) | 1.12 (0.92–2.03) | 1.62 (1.26–2.37) | .003 |
| LDH, U/L (IQR) | 203.0 (171.0–252.0) | 232.0 (194.0–303.0) | .002 |
| Medications | |||
| ACEi/ARB, n (%) | 2 (0.5) | 13 (18.3) | <.001 |
| β-blocker, n (%) | 8 (11.3) | 2 (0.5) | <.001 |
| CCB, n (%) | 1 (0.3) | 34 (47.9) | <.001 |
| Diuretics, n (%) | 2 (0.5) | 1 (1.4) | .374 |
| Statin, n (%) | 9 (2.2) | 6 (8.5) | .006 |
COPD: chronic obstructive pulmonary disease; AST: aspartate aminotransferase; UA: uric acid; CRP: C-reactive protein; LDH: lactate dehydrogenase; ACEi: angiotensin converting enzyme inhibitor; ARB: Ang II receptor blocker; CCB: calcium channel blocker; ICU: intensive care unit.